WO2022101931A1 - Process for the preparation of eribulin and its intermediates - Google Patents

Process for the preparation of eribulin and its intermediates Download PDF

Info

Publication number
WO2022101931A1
WO2022101931A1 PCT/IN2021/051053 IN2021051053W WO2022101931A1 WO 2022101931 A1 WO2022101931 A1 WO 2022101931A1 IN 2021051053 W IN2021051053 W IN 2021051053W WO 2022101931 A1 WO2022101931 A1 WO 2022101931A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
eribulin
preparation
stirred
Prior art date
Application number
PCT/IN2021/051053
Other languages
French (fr)
Inventor
Phaneendra Gutala
Srinivasu Kasa
Nagamani BRAHMADEVI
Balakrishna Reddy SIRIGIREDDY
Durga Prasad Konakanchi
Ramesh Dandala
Pulla Reddy Muddasani
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of WO2022101931A1 publication Critical patent/WO2022101931A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings

Definitions

  • the present invention relates to the process for the preparation of Eribulin and Eribulin Mesylate.
  • the present invention involves less expensive solvents and the process conditions can be easily adopted for commercial scale.
  • Eribulin is a synthetic macrocyclic analogs of halichondrin B, and is represented by structural formula as shown in below.
  • Eribulin is marketed as Eribulin Mesylate under the brand name HALAVEN® and it is indicated for the treatment of patients with metastatic breast cancer.
  • U.S. patent No 6214865 discloses Eribulin.
  • PCT application WO 2005/118565 discloses process for the synthesis of Eribulin Mesylate. The reported process suffer from major disadvantages, including low yield, low purity and formation of Eribulin isomers which are difficult to remove using conventional purification methods.
  • US9303039 discloses process for the preparation of Eribulin intermediate ER-811475 from ER- 118046 by reacting with tetrabutyl ammonium fluoride in a amide solvent like N, N-dimethylacetamide solvent.
  • the main object of the present invention is to provide a process for the preparation of Eribulin.
  • Yet another object of the present invention is to provide an Eribuhn intermediate compound of formula IIA.
  • the process is useful in the synthesis of Eribulin and Eribulin mesylate.
  • One Aspect of the present invention is to provide a process for the preparation an intermediate in the synthesis of Eribulin, said method comprising reacting a compound of formula compound of formula - 1 with fluoride source in a cyclic urea-based solvent to produce the intermediate compound of formula IIA.
  • the present invention is related to a process for the preparation of Eribulin and Eribulin mesylate, whereas the present process uses the cyclic urea-based solvent to produce the intermediate compound of formula IIA from compound of formula I intermediate.
  • One embodiment of the present invention is to provide a process for the preparation an intermediate in the synthesis of Eribulin, said method comprising reacting a compound of formula-I with fluoride source in a cyclic urea-based solvent to produce the intermediate compound of formula IIA.
  • a cyclic urea-based solvent is N, N- Dimethylpropyleneurea (DMPU) and N, N-Dimethylethyleneurea (DMEU).
  • the fluoride source is tetrabutylammonium fluoride.
  • Eribulin intermediate compound of formula I used in the present invention is prepared by the prior art process.
  • Cyclic urea-based solvents such as is N, N-Dimethylpropyleneurea (DMPU) and N, N-Dimethylethyleneurea (DMEU) are highly effective for converting compound of formula I to compound of formula IIA even at low temperatures such as 5-10 °C.
  • Example-1 Preparation of compound of formula I via Dess-martin oxidation:
  • reaction mass is diluted with 15.0 mL of 5% aqueous sodium bicarbonate solution, 15.0 mL of 20% aqueous sodium sulphite solution and 20 mL of dichloromethane. After stirring the biphasic mass for 10 minutes, separated the organic and aqueous layers.
  • Aqueous layer is extracted with 30.0 mL of dichloromethane. Combined organic layers are washed with 40 mL of DM water. Solvent is evaporated under reduced pressure at 30 °C to afford white colored foamy solid or thick oil. Charged 2x20 mL of n-heptane to the foamy solid and distilled out completely to get 1.99 g of compound of formula I as white foamy solid.
  • reaction mass is diluted with 900 mL of 20% aqueous NaCl solution and 900 mL of ethyl acetate and stirred for 20 min. Layers are separated and aqueous layer is re-extracted with 288 mL of ethyl acetate. Solvent is evaporated under reduced pressure at 35 °C to afford brown colored oil (25.87 g).
  • Brown residue thus obtained is co-distilled twice with MeCN/Water (6: 1), MeCN (2 x 10 V) and methylene chloride (3x20 V) to furnish compound of formula IIA crude (24.65 g) as brown colored oil which is used for compound of formula II formation (Example- V) without any further characterization.
  • Example-3 Preparation of compound of formula IIA: compound of formula IIA: Deprotection of TBS ethers employing Imidazole.HCL in a cyclic urea based solvent DMPU:
  • reaction mass is diluted with 50 mL of DM water and 50 mL of ethyl acetate and stirred for 15-20 min. Layers are separated and aqueous layer is reextracted with 16 mL of ethyl acetate. Solvent is evaporated under reduced pressure at 30 °C to afford brown colored oil. Brown residue thus obtained is co-distilled with (2x10 mL) of MeCN to furnish compound of formula IIA crude (0.8 g) as brown colored oil.
  • compound of formula IIA Crude HPLC result: compound of formula IIA -66.06% compound of formula IIA Isomer-6.15%
  • Example-4 Preparation of compound of formula IIA: compound of formula IIA: Deprotection of TBS ethers employing Imidazole.HCL in a cyclic urea based solvent DMEU:
  • reaction mass is stirred for 4-7 h at the same temperature and the progress of the reaction is monitored by HPLC. After the consumption of starting material (compound of formula IIA content judged by HPLC), reaction mass is diluted with 900.0 mL of DM water and 900 mL of MTBE. After stirring the biphasic mass for 10-15 minutes, separated the organic and aqueous layers. Aqueous layer is extracted with 2x900 mL of MTBE.
  • Example-6 Preparation of Eribulin free base from compound of formula II via selective tosylation by employing Dibutyldimethoxy tin:
  • reaction mass is stirred for 20-25 h at the same temperature and the progress of the reaction is monitored by HPLC. After the consumption of starting material (judged by HPLC), reaction mass is evacuated to get the crude. Subsequently, the crude is diluted with 7.0 mL of methylene chloride and aqueous solution of sodium bicarbonate and sodium carbonate (0.1 g of sodium bicarbonate and 0.1 g of sodium carbonate dissolved in 2.0 mL of DM water). After stirring the biphasic mass for 15 minutes, separated the organic and aqueous layers.
  • Enbulin free base crude (0.134 g).
  • Enbulin free base crude is purified by flash chromatography using acetonitrile and aqueous ammonium acetate as the eluent to afford 0.065 g of Eribulin free base as a white foamy solid. Purified sample is characterized by HPLC for its purity.
  • Example-8 Preparation of Eribulin mesylate from Eribulin PTSPA salt via

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a process for the preparation of Eribulin Intermediates. The present invention involves less expensive solvents and the process conditions can be easily adopted for commercial scale.

Description

PROCESS FOR THE PREPARATION OF ERIBULIN AND ITS
INTERMEDIATES
Field of the invention: The present invention relates to the process for the preparation of Eribulin and Eribulin Mesylate. The present invention involves less expensive solvents and the process conditions can be easily adopted for commercial scale.
Background of the Invention: Eribulin, is a synthetic macrocyclic analogs of halichondrin B, and is represented by structural formula as shown in below.
Figure imgf000002_0001
Eribulin mesylate (II)
Eribulin is marketed as Eribulin Mesylate under the brand name HALAVEN® and it is indicated for the treatment of patients with metastatic breast cancer. U.S. patent No 6214865 discloses Eribulin. PCT application WO 2005/118565 discloses process for the synthesis of Eribulin Mesylate. The reported process suffer from major disadvantages, including low yield, low purity and formation of Eribulin isomers which are difficult to remove using conventional purification methods.
US9303039 discloses process for the preparation of Eribulin intermediate ER-811475 from ER- 118046 by reacting with tetrabutyl ammonium fluoride in a amide solvent like N, N-dimethylacetamide solvent.
Figure imgf000003_0001
Hence, there remains a need to provide an alternative process for the preparation of high pure Eribulin and Eribulin Mesylate.
Objects of the Invention:
The main object of the present invention is to provide a process for the preparation of Eribulin. Yet another object of the present invention is to provide an Eribuhn intermediate compound of formula IIA.
Summary of the Invention:
According to a first aspect of the present invention, the process is useful in the synthesis of Eribulin and Eribulin mesylate.
One Aspect of the present invention is to provide a process for the preparation an intermediate in the synthesis of Eribulin, said method comprising reacting a compound of formula compound of formula - 1 with fluoride source in a cyclic urea-based solvent to produce the intermediate compound of formula IIA.
Figure imgf000004_0001
Detailed description of the Invention:
The present invention is related to a process for the preparation of Eribulin and Eribulin mesylate, whereas the present process uses the cyclic urea-based solvent to produce the intermediate compound of formula IIA from compound of formula I intermediate.
One embodiment of the present invention is to provide a process for the preparation an intermediate in the synthesis of Eribulin, said method comprising reacting a compound of formula-I with fluoride source in a cyclic urea-based solvent to produce the intermediate compound of formula IIA.
Figure imgf000005_0001
According to the present invention a cyclic urea-based solvent is N, N- Dimethylpropyleneurea (DMPU) and N, N-Dimethylethyleneurea (DMEU).
According to the present invention the fluoride source is tetrabutylammonium fluoride.
The Present invention is further illustrated in detail with reference to following examples. It is desired that the examples be considered in all respect as illustrative and are not intended to limit the scope of the invention in any way.
According to the present invention, Eribulin intermediate compound of formula I used in the present invention is prepared by the prior art process.
Advantages of the Present Invention:
1. Cyclic urea-based solvents such as is N, N-Dimethylpropyleneurea (DMPU) and N, N-Dimethylethyleneurea (DMEU) are highly effective for converting compound of formula I to compound of formula IIA even at low temperatures such as 5-10 °C.
2. Selectivity between compound of formula IIA and compound of formula IIA isomer induced by DMPU is as high as 20: 1.
3. Since, DMPU and DMEU are highly soluble in water, it could be easily removed by extractive work-up with aqueous sodium chloride. The Present invention is further illustrated in detail with reference to following examples. It is desired that the examples be considered in all respect as illustrative and are not intended to limit the scope of the invention in any way.
Examples:
Example-1: Preparation of compound of formula I via Dess-martin oxidation:
Figure imgf000006_0001
To a stirred and pre-cooled (10-20 °C) solution of compound of formula IA (2.0 g) in dichloromethane (40 mL), charged 0.96 g of Dess-Martin Periodinane. The resulting white slurry is stirred for 2-4 h at the same temperature and the progress of the reaction is monitored by HPLC. After the consumption of starting material (judged by HPLC), reaction mass is diluted with 15.0 mL of 5% aqueous sodium bicarbonate solution, 15.0 mL of 20% aqueous sodium sulphite solution and 20 mL of dichloromethane. After stirring the biphasic mass for 10 minutes, separated the organic and aqueous layers. Aqueous layer is extracted with 30.0 mL of dichloromethane. Combined organic layers are washed with 40 mL of DM water. Solvent is evaporated under reduced pressure at 30 °C to afford white colored foamy solid or thick oil. Charged 2x20 mL of n-heptane to the foamy solid and distilled out completely to get 1.99 g of compound of formula I as white foamy solid.
HPLC Purity: 97.74%
’H NMR 400 MHz, CDC13: 5 7.305-7.250 (m, 1 H), 6.35 (d, 1H, 7=15.6 Hz), 5.026- 5.005 (m, 2H), 4.897-4.788 (m, 3H), 1.053 (bs, 1H), 4.083-4.036 (m, 3H), 3.916-3.780 (m, 5H), 3.704 (m, 1H), 3.535 (ddd, 3H, 7=15.6, 10.4, 5.6 Hz), 3.43 (d, 2H, 7=2.8 Hz), 3.314 (s, 3H), 2.963-2.939 (m, 1H), 2.862 (dd, 1H, 7=15.6, 7.2 Hz), 2.760-2.625 (m, 4H), 2.547-2.433 (m, 3H), 2.309-2.271 (m, 2H), 2.081-2.030 (m, 1H), 1.984-1.885 (m, 2H), 1.832-1.671 (m, 7H), 1.471-1.403 (m, 1H), 1.354-1.307 (m, 2H), 1.26 (bs, 3H), 1.091-1.029 (m, 4H), 0.982-0.946 (m, 17H), 0.891-0.881 (m, 26H), 0.203 (bs, 3H), 0.146-0.133 (m, 9H), 0.076 to -0.037 (m, 21H).
Example-2: Preparation of compound of formula HA:
Deprotection of TBS ethers employing TBAF and Imidazole.HCL in a cyclic urea based solvent DMPU:
Figure imgf000007_0001
Weighed 0.884 g of imidazole hydrochloride in an inert atmosphere Glove box and transferred into an appropriate flask. Charged 17.8 mL of tetrabutylammonium fluoride (1.0 M solution in THF), to the flask containing imidazole hydrochloride and stirred at room temperature for 10-15 minutes. Subsequently, Tetrahydrofuran in the reaction mass was evaporated completely by connecting the reaction flask to a vacuum port. The thick mass thus obtained was cooled to 5-10 °C and was charged with N,N- Dimethylpropyleneurea (DMPU) solution of compound of formula I (3.6 g dissolved in 90.0 mL of DMPU). The resulting solution is stirred at the same temperature for 12- 20 h until the completion of reaction (monitored by HPLC). Following the completion of reaction, reaction mass is diluted with 900 mL of 20% aqueous NaCl solution and 900 mL of ethyl acetate and stirred for 20 min. Layers are separated and aqueous layer is re-extracted with 288 mL of ethyl acetate. Solvent is evaporated under reduced pressure at 35 °C to afford brown colored oil (25.87 g). Brown residue thus obtained is co-distilled twice with MeCN/Water (6: 1), MeCN (2 x 10 V) and methylene chloride (3x20 V) to furnish compound of formula IIA crude (24.65 g) as brown colored oil which is used for compound of formula II formation (Example- V) without any further characterization.
HPLC result: compound of formula IIA -56.49% compound of formula IIA Isomer-2.57%.
Example-3: Preparation of compound of formula IIA: compound of formula IIA: Deprotection of TBS ethers employing Imidazole.HCL in a cyclic urea based solvent DMPU:
Figure imgf000008_0001
Weighed 0.048 g of imidazole hydrochloride in an inert atmosphere Glove box and transferred into an appropriate flask containing 1.0 mL of N,N-Dimethylpropyleneurea (DMPU). Subsequently, charged 0.308 g of solid tetrabutylammonium fluoride trihydrate (TBAF.3H2O) to the above flask and stirred at room temperature for 10-15 minutes. The resulting solution thus obtained was cooled to 5-10 °C and was charged with N,N-Dimethylpropyleneurea (DMPU) solution of compound of formula I (0.2 g dissolved in 5.0 mL of DMPU). The resulting solution is stirred at the same temperature for 5 h until the completion of reaction (monitored by HPLC). Following the completion of reaction, reaction mass is diluted with 50 mL of DM water and 50 mL of ethyl acetate and stirred for 15-20 min. Layers are separated and aqueous layer is reextracted with 16 mL of ethyl acetate. Solvent is evaporated under reduced pressure at 30 °C to afford brown colored oil. Brown residue thus obtained is co-distilled with (2x10 mL) of MeCN to furnish compound of formula IIA crude (0.8 g) as brown colored oil. compound of formula IIA Crude HPLC result: compound of formula IIA -66.06% compound of formula IIA Isomer-6.15%
Example-4: Preparation of compound of formula IIA: compound of formula IIA: Deprotection of TBS ethers employing Imidazole.HCL in a cyclic urea based solvent DMEU:
Figure imgf000009_0001
Weighed 0.024 g of imidazole hydrochloride in an inert atmosphere Glove box and transferred into an appropriate flask. Charged 0.49 mL of tetrabutylammonium fluoride (1.0 M solution in THF), to the flask containing imidazole hydrochloride and stirred at room temperature for 10-15 minutes. The resulting solution thus obtained was cooled to 15-20 °C and was charged with N,N-Dimethylethyleneurea (DMEU) solution of compound of formula - 1 (0.1 g dissolved in 2.5 mL of DMEU). The resulting solution is stirred at the same temperature for 12 h until the completion of reaction (monitored by HPLC). Formation of the product is confirmed by HPLC.
HPLC result: compound of formula - IIA: 49.17% compound of formula - IIA Isomer-5.43% Example-5: Preparation of compound of formula II employing PPTS for ketalization of compound of formula IIA:
Mi
Figure imgf000010_0001
To a stirred and pre-cooled (15-20 °C) solution of compound of formula IIA crude (24.6 g) in dichloromethane (90.0 mL), charged methylene chloride solution of PPTS (3.43 g of PPTS in 18 mL of MDC). Reaction mass is stirred for 4-7 h at the same temperature and the progress of the reaction is monitored by HPLC. After the consumption of starting material (compound of formula IIA content judged by HPLC), reaction mass is diluted with 900.0 mL of DM water and 900 mL of MTBE. After stirring the biphasic mass for 10-15 minutes, separated the organic and aqueous layers. Aqueous layer is extracted with 2x900 mL of MTBE. Combined organic layers are washed with 3x900 mL of aqueous 10% sodium chloride solution. Organic layer is dried over sodium sulphate and solvent is evaporated under reduced pressure at 30 °C to afford compound of formula II crude as thick oil (1.7 g). compound of formula II crude was purified by flash chromatography at first for the removal of DMPU and subsequently by Prep-HPLC for the removal of compound of formula IIA isomer to afford 0.82g of pure compound of formula II.
HPLC Purity of compound of formula II Crude: compound of formula II -66.05%; compound of formula IIA -Isomer- 1.65% HPLC Purity of compound of formula II punned by Prep-HPLC: compound of formula II: 99.88% compound of formula IIA Isomer: Not detected. compound of formula II: 0.08%
’H NMR 400 MHz, CD3OD: 5 5.142 (d, 1H, 7=1.2 Hz), 5.029 (bs, 1H), 4.83 (d, 1H, 7=1.2 Hz), 4.711 (t, 1H, 7=4.8 Hz), 4.615 (t, 1H, 7=4.4 Hz), 4.484 (d, 1H, 7=10.8 Hz), 4.329-4.269 (m, 2H), 4.183 (dd, 1H, 6.4, 4.4 Hz), 4.118 (dd, 1H, 7=6.0, 4.0 Hz), 4.077 (bs, 1H), 3.987 (t, 1H, 7=10.4 Hz), 3.886-3.839 (m, 3H), 3.744-3.656 (m, 2H), 3.49 (ddd, 2H, 7=19.6, 11.2, 4.4 Hz), 3.422 (s, 3H), 3.355 (d, 1H, 7=4.0 Hz), 3.211 (s, 2H), 2.947-2.918 (m, 2H), 2.764-2.648 (m, 2H), 2.475-2.301 (m, 5H), 2.207-(m, 4H), 2.032- 1.957 (m, 3H), 1.902-1.857 (m, 2H), 1.794-1.690 (m, 4H), 1.601-1.291 (m, 7H), 1.111 (d, 3H, 7=6.4 Hz), 1.069-0.979 (m, 1H).
13C NMR 100 MHz, CD3OD:
5 208.184, 154.310, 153.122, 111.051, 105.148, 105.017, 87.889, 83.950, 82.527, 82 .031,
79.464, 78.521, 77.988, 77.781, 75.975, 75.504, 75.312, 74.671, 74.473, 74.324, 74.2 83, 71.297, 69.798, 67.389, 57.365, 44.988, 44.869, 40.036, 39.563, 36.795, 36.306, 33.065, 32.694, 32.103, 31.213, 29.822, 27.200, 18.433.
Example-6: Preparation of Eribulin free base from compound of formula II via selective tosylation by employing Dibutyldimethoxy tin:
Figure imgf000012_0001
To a stirred solution of compound of formula II (0.1 g) in acetonitrile (1.5 mL), charged an acetonitrile solution (0.2 mL) of dibutyldimethoxytin (2 mg) and N, N- diisopropylethylamine (72 pL). After stirring the above mass for 10 minutes at ambient temperature, charged an acetonitrile solution (0.5 mL) of para-toluenesulfonyl chloride (0.077 g). The resulting mass is stirred for 4-6 h at the room temperature and the progress of the reaction is monitored by HPLC. After the consumption of starting material (compound of formula II content judged by HPLC), reaction mass is diluted with isopropyl alcohol (11 mL) and transferred into an appropriately sized flask for transforming it to the subsequent stages without any further characterization.
To the above stirred solution of reaction mass in isopropyl alcohol (11 mL), charged 12.6 mL of ammonia solution at room temperature. Reaction mass is stirred for 20-25 h at the same temperature and the progress of the reaction is monitored by HPLC. After the consumption of starting material (judged by HPLC), reaction mass is evacuated to get the crude. Subsequently, the crude is diluted with 7.0 mL of methylene chloride and aqueous solution of sodium bicarbonate and sodium carbonate (0.1 g of sodium bicarbonate and 0.1 g of sodium carbonate dissolved in 2.0 mL of DM water). After stirring the biphasic mass for 15 minutes, separated the organic and aqueous layers. Aqueous layer is extracted with 4.0 mL of dichloromethane. Solvent is evaporated under reduced pressure at 30 C to afford Enbulin free base crude (0.134 g). Enbulin free base crude is purified by flash chromatography using acetonitrile and aqueous ammonium acetate as the eluent to afford 0.065 g of Eribulin free base as a white foamy solid. Purified sample is characterized by HPLC for its purity.
HPLC Purity: 90.04%.
Example-7: Preparation of Eribulin PTSPA salt from Eribulin Free Base:
Figure imgf000013_0001
To a stirred solution of acetonitrile (100 ml) was added Eribulin free base (2.0 g) at 20- 30 °C and stirred the mass for 10-15 minutes at 20-30 °C. Dissolved the 2V-(p-Toluene sulfonyl)-L-phenyl alanine (PTSPA) (0.875 g) in acetonitrile (50 mL) and added slowly to the Eribulin free base solution at 20-30 °C. Stirred the reaction mass for 60 minutes at 20-30 °C and filtered the solid and washed the cake with 25 ml of acetonitrile and dried under vacuum at 30-35 °C for 3 hours.
Dry weight: - 2.35 g
Purity by HPLC: - 99.69%
Example-8: Preparation of Eribulin mesylate from Eribulin PTSPA salt via
Eribulin free base (pure)
Figure imgf000013_0002
Preparation of Pure Enbuhn free base
To a stirred Eribulin PTSPA salt (2.74 g) charged dichloromethane (300 ml) at 20-30 °C and charged DM water (150 ml) at 20-30 °C and cooled the reaction mass to 10-15 °C and charged aqueous ammonia solution (3.0 ml) at 10-15 °C and stirred the mass for 20 minutes (pH « 9.7), separated the organic layer and aqueous layer, extracted the aqueous layer with dichloromethane (150 ml), separated the organic layer and aqueous layer, combined the organic layer and washed with DM water (150 ml), distilled the dichloromethane layer under vacuum at below 30 °C to obtain Pure Eribulin free base (1-905 g).
Purity by HPLC: 99.068%
Preparation of Eribulin Mesylate:
To a stirred solution of pure Eribulin free base (1.9 g), charged acetonitrile (70 ml) at 20-30 °C, charged aqueous ammonia solution (3 ml) at 20-30 °C, charged ammonium methane sulfonate (0.3 g) with acetonitrile (10 ml). Stirred the reaction mass for 30 minutes at 20-30 °C. Distilled the reaction mass at below 30 °C and obtained thick oil residue. Co-distilled the reaction mass with acetonitrile (20 ml) under vacuum at below 30 °C and obtained thick solid. Charged 75% dichloromethane in n-Pentane (40 ml) at 20-30 °C. Stirred for 10 minute and filtered the solution. Distilled the filtrate under vacuum at below 30 °C and obtained solid, dissolved the above solid in 50% dichloromethane in n-pentane (40 ml) and filtered the particles, the filtrate was added slowly into n-pentane (225 ml) in another RB flask at 20-30 °C. Stirred the mass for 16 hours at 20-30 °C. Filtered the solid under nitrogen pressure and washed with n- pentane (50 ml), Dried the compound under vacuum at 20-30 °C for 60 minutes.
Dry weight: 1.70 g.
The overall yield of Eribulin mesylate obtained from Eribulin PTSPA salt:-79% Purity by HPLC: 99.416%

Claims

We Claim:
1. A process for the preparation of Eribulin Intermediate Compound of formula- IIA by reacting a compound of formula-I with fluoride source in a cyclic urea-based solvent to produce the intermediate Compound of formula -II A.
Figure imgf000015_0001
2. The process as claimed in claim 1, wherein the cyclic urea-based solvent is selected from N, N-Dimethylpropylene urea (DMPU) and N, N- Dimethylethylene urea (DMEU).
3. The process as claimed in claim 1, wherein the fluoride source is tetrabutylammonium fluoride.
4. The process as claimed in claim 1, wherein the intermediate Compound of formula -II A is further converted to Eribulin.
PCT/IN2021/051053 2020-11-10 2021-11-06 Process for the preparation of eribulin and its intermediates WO2022101931A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041048990 2020-11-10
IN202041048990 2020-11-10

Publications (1)

Publication Number Publication Date
WO2022101931A1 true WO2022101931A1 (en) 2022-05-19

Family

ID=81602332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/051053 WO2022101931A1 (en) 2020-11-10 2021-11-06 Process for the preparation of eribulin and its intermediates

Country Status (1)

Country Link
WO (1) WO2022101931A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085193A1 (en) * 2013-12-06 2015-06-11 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085193A1 (en) * 2013-12-06 2015-06-11 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs

Similar Documents

Publication Publication Date Title
EP3580219B1 (en) Process for the preparation of remimazolam and solid state forms of remimazolam salts
DE69332438T2 (en) 7-HALO AND 7 (BETA), 8 (BETA) METHANO TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP6013326B2 (en) Process for the preparation of chiral triazolones
MX2012008510A (en) Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs.
CZ291205B6 (en) Rapamycin derivatives and immunosuppression induction method
CZ292993B6 (en) Method for the preparation of an oxazoline sidechain-bearing taxane and taxane prepared in such a manner that
KR20040018538A (en) Reductive cleavage of the exocyclic ester of UK-2A or its derivatives and products formed therefrom
EP3152191B1 (en) Improved process for making duocarmycin prodrugs
NO317832B1 (en) 7-deoxy- <delta> <O> 12 </O>, <O> 13 </O> -isotaxol analogues and pharmaceutical preparations containing these
WO2022101931A1 (en) Process for the preparation of eribulin and its intermediates
US9434740B2 (en) Taxane compounds, compositions and methods
EP2913329B1 (en) Method for manufacturing difluoro lactone compound
JP2024530795A (en) Synthesis of Nirogacestat
AU2013368947B2 (en) Process for preparing amorphous Cabazitaxel
EP3114112B1 (en) Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
WO2016090461A1 (en) Salts of prostaglandin analog intermediates
EP4112612A1 (en) Intermediate useful for synthesis of sglt inhibitor and method for preparing sglt inhibitor using same
CZ2009417A3 (en) Novel process for preparing 2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-(1H-pyrrol-1-yl) 1H-benzimidazole (ilaprazole)
WO2013162922A1 (en) Taxane compounds, compositions and methods
WO2022094711A1 (en) Process for preparation of advanced intermediate for eribulin synthesys
US9284327B2 (en) Taxane compounds, compositions and methods
CA3210591A1 (en) Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
WO2016157057A1 (en) A process for preparation of sodium salt of (2s, 5r) sulfuric acid mono-(2-[1,3,4]oxadiazol-2-yl-7-oxo-1,6-diazabicyclo[3.2.1 ]oct-6-yl)ester
JPH05271238A (en) New sf2370 derivative
HU179987B (en) Process for preparing citric acid derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21891383

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21891383

Country of ref document: EP

Kind code of ref document: A1